CC
CBIO

Commodore Capital’s Crescent Biopharma CBIO Stock Holding History

Commodore Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-450,829
Closed -$5.36M – 38
2025
Q3 		$5.36M Sell
450,829
-2,857
-0.6% -$37.9K 0.26% 37
2025
Q2 		$7.32M Buy
+453,686
New +$9.6M 0.52% 30

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Commodore Capital's CBIO Position: Q4 2025 in Review

Commodore Capital sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 450,829 shares — an estimated $5.36M sold.

Commodore Capital first reported a position in CBIO in Q2 2025 and held it in 2 quarters. The position peaked at $7.32M in Q2 2025. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Commodore Capital reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Commodore Capital sold 450,829 Crescent Biopharma shares in Q4 2025, an estimated $5.36M.
  • Commodore Capital first reported a position in Crescent Biopharma in Q2 2025 and held it in 2 quarters.
  • Commodore Capital's Crescent Biopharma position peaked at $7.32M in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Commodore Capital's 13F filing for Q4 2025, filed 17 Feb 2026.